India indigenous COVAXIN shows 81% efficacy |
India`s Indigenously developed Covid-19 vaccine named Covaxin has shown interim clinical efficacy of 81 percent in its phase 3 trial. The trial involved 25 thousand 800 participants across 21 sites. The first interim analysis based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group resulted in a vaccine efficacy of 81 percent. The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research. Director-General of Indian Council of Medical Research, Dr. Balram Bhargava said that the journey of completely indigenous COVID-19 vaccine in less than eight months` time showcases the immense strength of Atma Nirbhar Bharat. He said it is also a testament to India`s emergence as a global vaccine superpower. Meanwhile, the Indian Government has allowed round-the-clock COVID-19 vaccination in order to expedite the immunization drive. In a tweet, Health Minister Harsh Vardhan said the government has lifted the time restriction to increase the speed of vaccination. He said people can now get vaccinated 24 by 7 according to their convenience. Dr. Harsh Vardhan said that this shows Prime Minister Narendra Modi`s belief in the value of health as well as the time of citizens. All private hospitals were on 2nd March allowed to give the vaccines if they adhere to the laid down norms, anytime as the 9 am to 5 pm timing was also done away with.
|
|
|
|